The efficacy of botulinum toxin type A injection in treatment of myofacial pain dysfunction syndrome A randomized placebo controlled clinical trial

Volume 20 No 3 (2022)

Dr. Rania Hassan Shalaby,Prof. Sandy Hassan Shaaban,Dr. Ashraf Abd El Rahim,Dr. Christine Raouf George Mikhail

DOI: 10.48047/NQ.2022.20.3.NQ22937

Abstract

Objectives: The purpose of the current research was to evaluate the effectiveness of utilizing botulinum toxin (BTX) for treating myofascial pain from the masseter, temporalis, and lateral pterygoid muscles in patients with temporo-mandibular joint problems. Subjects and Methods: There were 29 participants in the study who had been diagnosed with masseter and temporalis myofascial pain. They were randomly assigned to 1 of 2 treatment groups, either group A (Intervention n=15), which received 100 U of botulinum toxin type A (BTX-A) injected at MTrP per masseter, temporalis, and lateral pterygoid muscles, or group B (Placebo n=14), which received treatment with At first, visual analogue scales for pain and pressure algometry were used., at 2 weeks, 1 and 3 months of BTX type A injections (study group A) and placebo (control group B).

Keywords

botulinum toxin; temporomandibular joint disorders; myofascial pain

Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.